Gil Blum
Stock Analyst at Needham
(3.78)
# 658
Out of 5,179 analysts
427
Total ratings
37.97%
Success rate
11.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Buy | $10 → $11 | $2.03 | +441.87% | 19 | Mar 26, 2026 | |
| CELC Celcuity | Reiterates: Buy | $122 | $109.14 | +11.78% | 24 | Mar 26, 2026 | |
| ABSI Absci | Reiterates: Buy | $7 | $2.79 | +150.90% | 9 | Mar 25, 2026 | |
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $18 | $4.92 | +265.85% | 8 | Mar 11, 2026 | |
| IMCR Immunocore Holdings | Maintains: Buy | $71 → $75 | $29.73 | +152.27% | 15 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Hold | n/a | $114.65 | - | 26 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $80 → $82 | $46.46 | +76.50% | 28 | Feb 13, 2026 | |
| MREO Mereo BioPharma Group | Maintains: Buy | $5 → $3 | $0.33 | +821.38% | 21 | Jan 13, 2026 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.20 | +733.33% | 34 | Jan 12, 2026 | |
| GERN Geron | Reiterates: Buy | $6 | $1.48 | +306.78% | 23 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | n/a | $19.90 | - | 39 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $7.16 | +165.36% | 4 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $4.11 | +192.33% | 33 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $5.74 | +631.71% | 17 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.96 | +170.27% | 26 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $14.94 | +74.03% | 29 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $14.42 | - | 8 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $6 | $0.97 | +517.73% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.15 | - | 9 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $3.86 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $6.04 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $10.19 | +371.05% | 9 | Aug 2, 2024 |
Nkarta
Mar 26, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $2.03
Upside: +441.87%
Celcuity
Mar 26, 2026
Reiterates: Buy
Price Target: $122
Current: $109.14
Upside: +11.78%
Absci
Mar 25, 2026
Reiterates: Buy
Price Target: $7
Current: $2.79
Upside: +150.90%
Artiva Biotherapeutics
Mar 11, 2026
Reiterates: Buy
Price Target: $18
Current: $4.92
Upside: +265.85%
Immunocore Holdings
Feb 26, 2026
Maintains: Buy
Price Target: $71 → $75
Current: $29.73
Upside: +152.27%
Arcellx
Feb 23, 2026
Downgrades: Hold
Price Target: n/a
Current: $114.65
Upside: -
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Buy
Price Target: $80 → $82
Current: $46.46
Upside: +76.50%
Mereo BioPharma Group
Jan 13, 2026
Maintains: Buy
Price Target: $5 → $3
Current: $0.33
Upside: +821.38%
Autolus Therapeutics
Jan 12, 2026
Maintains: Buy
Price Target: $11 → $10
Current: $1.20
Upside: +733.33%
Geron
Aug 9, 2024
Reiterates: Buy
Price Target: $6
Current: $1.48
Upside: +306.78%
Mar 26, 2026
Reiterates: Underperform
Price Target: n/a
Current: $19.90
Upside: -
Mar 20, 2026
Reiterates: Buy
Price Target: $19
Current: $7.16
Upside: +165.36%
Mar 19, 2026
Maintains: Buy
Price Target: $10 → $12
Current: $4.11
Upside: +192.33%
Mar 9, 2026
Reiterates: Buy
Price Target: $42
Current: $5.74
Upside: +631.71%
Feb 26, 2026
Reiterates: Buy
Price Target: $8
Current: $2.96
Upside: +170.27%
Jan 29, 2026
Reiterates: Buy
Price Target: $26
Current: $14.94
Upside: +74.03%
Dec 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $14.42
Upside: -
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $0.97
Upside: +517.73%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.15
Upside: -
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $3.86
Upside: -
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $6.04
Upside: -
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $10.19
Upside: +371.05%